infection immediately upon notifying medical staff of symptom onset. These results must be reported to CDC in aggregate through the EDC form.

Shoreside COVID–19 Laboratory Screening Testing of All Embarking Crew

(1) On the day of crew members’ embarkation, cruise ship operators must collect specimens for SARS-CoV–2 testing from all embarking land-based crew. Cruise ship operators must immediately transport the specimens to a CLIA-certified laboratory for testing.

(2) This laboratory must use an RT–PCR test that has been approved, cleared, or authorized for emergency use by FDA. Cruise ship operators must report results in aggregate to CDC through the EDC form. CDC must approve the cruise ship operator’s selection of a CLIA-certified laboratory.

(3) All embarking land-based crew must be immediately quarantined onboard for 14 days. Those who test positive must be isolated until criteria are met for discontinuation of isolation according to the most current CDC guidance. CDC may also oversee the collection of specimens, or the quarantine or isolation of embarking crew, through remote means allowing for visual observation.

Continued Compliance With No Sail Order (NSO) Response Plans

(1) Cruise ship operators must continue to follow their cruise lines’ complete, accurate, and acknowledged NSO response plans per the No Sail Order and Suspension of Further Embarkation; Notice of Modification and Extension and Other Measures Related to Operations published at 85 FR 21004 (April 15, 2020) (i.e., “No Sail Order response plan”), as modified and extended July 16, 2020 (published at 85 FR 44085 [July 21, 2020]), and September 30, 2020 (published at 85 FR 62732 (October 5, 2020)).

(2) Cruise ship operators must also continue to follow CDC’s Interim Guidance for Mitigation of COVID–19 Among Cruise Ship Crew and COVID–19 Color-coding System for Cruise Ships, which may be modified or updated as needed. CDC will notify cruise ship operators of any updates. Ship-to-ship crew transfers and embarkations may continue to impact ships’ color-coding status. For additional information about other public health preventive measures, such as social distancing, mask use, and cabin occupancy, refer to CDC’s Interim Guidance.

Effective Date and Signature

This Order is effective upon signature and shall remain in effect until the earliest of (1) the expiration of the Secretary of Health and Human Services’ declaration that COVID–19 constitutes a public health emergency; (2) the CDC Director rescinds or modifies the order based on specific public health or other considerations; or (3) November 1, 2021.

Authority: The authority for these orders is Sections 361 and 365 of the Public Health Service Act (42 U.S.C. 264, 268) and 42 CFR 70.2, 71.31(b), 71.32(b).


Nina B. Witkofsky,
Acting Chief of Staff, Centers for Disease Control and Prevention.

[FR Doc. 2020–24477 Filed 10–30–20; 4:15 pm]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day–21–20PA]

Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled “DOP Cross-Site Program Implementation Evaluation of Overdose Data to Action Program” to the Office of Management and Budget (OMB) for review and approval. CDC previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on 06/15/2020 to obtain comments from the public and affected agencies. CDC did not receive public comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication.

Proposed Project


Background and Brief Description

The Overdose Data to Action (OD2A) program is a comprehensive, national overdose prevention program developed by CDC. The purpose of the OD2A program is to support funded jurisdictions in obtaining high quality, complete, and timely data on opioid prescribing and overdoses, and to use those data to inform prevention and response efforts. OD2A funds a total of 66 recipients (state and local health departments) to implement surveillance and prevention strategies, through a three-year cooperative agreement.

This information collection review is focused on the tools needed to evaluate the unique OD2A program. This information collection includes key informant interviews (KII) and focus groups (FG). The information collection is unique and will be the first evaluation of the OD2A program. There are no other efforts that CDC knows of to obtain program information required to
demonstrate impact and improve implementation of OD2A. The purpose of this information collection is to assess the implementation and the effectiveness of the OD2A program activities and identify the conditions under which these activities are most effective, and for whom. The implementation evaluation will identify the barriers and facilitators associated with deploying several prevention activities targeting specific populations within specific jurisdictions.

Data collected from this evaluation will be used by the CDC to obtain valid information regarding how recipients operationalized and implemented their chosen prevention activities, to assess the impact of OD2A and different components of OD2A on the trajectory of the opioid epidemic, and through the provision of these data back to the recipients, to improve the implementation and impact of further OD2A prevention activities. There are no costs to the respondents other than their time. The total estimated annualized burden hours are 574.

**ESTIMATED ANNUALIZED BURDEN HOURS**

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jurisdictions implementing OD2A program</td>
<td>Key Informant Interview Guides ..................</td>
<td>181</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Focus Group Guides ................................</td>
<td>165</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Permission to be Recorded ........................</td>
<td>346</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Interview Recruitment Email ........................</td>
<td>181</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Focus Group Recruitment Email ....................</td>
<td>165</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Interview Recruitment Reminder Email ...........</td>
<td>181</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Focus Group Recruitment Reminder Email ...</td>
<td>165</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Post-information Collection Follow up Email ...</td>
<td>346</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Program Manager Focus Group Recruitment Request Email</td>
<td>165</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td></td>
<td>Program Manager Interview Recruitment Request Email</td>
<td>181</td>
<td>1</td>
<td>5/60</td>
</tr>
</tbody>
</table>

*Jeffrey M. Zirger,*

[FR Doc. 2020–24473 Filed 11–3–20; 8:45 am]
BILLING CODE 4163–18–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**[30Day–21–20OG]**

**Agency Forms Undergoing Paperwork Reduction Act Review**

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled “Assessments of adults’ professional experiences for improving programs to decrease sexual risk and related behaviors and adverse health outcomes among youth,” to the Office of Management and Budget (OMB) for review and approval. CDC previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on June 2, 2020 to obtain comments from the public and affected agencies. CDC did not receive comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies’ estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication.

**Proposed Project**

Assessments of adults’ professional experiences for improving programs to decrease sexual risk and related behaviors and adverse health outcomes among youth—New—Division of Adolescent and School Health, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC).

**Background and Brief Description**

The Centers for Disease Control and Prevention (CDC) requests approval for a new generic information collection package that supports collection of quantitative and qualitative information from adults who help implement programs and services designed to prevent HIV, other sexually transmitted diseases (STDs), and pregnancy or influence related risk and protective factors; data will be collected for needs